Second Amendment to the Exclusive IP License Agreement for RQ-00000007 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.Exclusive Ip License Agreement • March 14th, 2017 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This is the Second Amendment (“Second Amendment”) to the Exclusive IP License Agreement for RQ-00000007 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on January 2nd, 2017 (the “Second Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 14th, 2017 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Loan and Security Agreement (the “Amendment”) is entered into as of February 24, 2017, by and among Pacific Western Bank, a California state chartered bank (“PWB”), in its capacity as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Agreement (as defined below) or otherwise a party thereto from time to time, including PWB in its capacity as a Lender and Oxford Finance LLC, a Delaware limited liability company (each a “Lender” and collectively, the “Lenders”), and Aratana Therapeutics, Inc., a Delaware corporation (“Parent”) and Vet Therapeutics, Inc., a Delaware corporation (individually and collectively, jointly and severally, “Borrower”).
Second Amendment to the Exclusive IP License Agreement for RQ-00000005 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.Exclusive Ip License Agreement • March 14th, 2017 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This is the Second Amendment (“Second Amendment”) to the Exclusive IP License Agreement for RQ-00000005 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on January 2nd, 2017 (the “Second Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
